PainChek Ltd (ASX:PCK) had a busy March quarter working towards commercialisation in Australia for its pain assessment tools.
PainChek™ is the world’s first smartphone pain assessment and monitoring device that detects pain through facial recognition technology using a smartphone or tablet.
Targeting people with dementia
Clinical studies conducted in Australian residential aged care centres, have been published in the Journal of Alzheimer’s Disease.
The published article indicates that PainChek™ is a valid and reliable pain assessment tool for people with moderate to severe dementia, who can no longer self-report their pain.
It also offers significant advantages over the current pain assessment methods.
Third residential aged care operator added during March quarter
The company signed one new residential aged care (RAC) operator during the March quarter in addition to its two existing clients.
These are annual contracts paying a standard list price of $10 per month per resident.
This is in addition to the Dementia Support Australia (DSA) agreement, for which the company has completed the first phase roll-out in Western Australia and South Australia.
Taking PainChek™ global
During April, the FDA confirmed the review of its submitted application is nearing completion and the company expects FDA clearance before the end of calendar 2018.
As well as the US, the company is receiving overseas interest including UK and Germany supporting a future international market strategy.
In parallel, the development of the next phase apps remains on track with the adult’s consumer version scheduled for the current June quarter and children’s app by the end of the December quarter.